Chimerix Azione

Chimerix Debito/EBITDA

Delisted·17 apr 2025

Rapporto Debiti Totali / EBITDA di Chimerix (CMRX) al 25 ago 2026.

Debito/EBITDA

0,00

Ultimo aggiornamento:

Rapporto Debiti Totali / EBITDA di Chimerix ammonta a 2026 0,00 . Rapporto Debiti Totali / EBITDA di Chimerix ammontava a 2025 0,00 . Diminuisce del % inferiore rispetto all'anno precedente.

La storia di Chimerix Debito/EBITDA

  • 3 anni

  • 10 anni

  • 25 anni

  • Max

Debito/EBITDA
Date
Debito/EBITDA
1 gen 2017
0,00 USD
1 gen 2018
0,00 USD
1 gen 2019
0,00 USD
1 gen 2020
0,00 USD
1 gen 2021
-0,08 USD
1 gen 2022
0,00 USD
1 gen 2023
0,00 USD
1 gen 2024
0,00 USD
La storia di Chimerix Debito/EBITDA
ANNODebito/EBITDAYoY
0,00
0,00
0,00-100,00%
-0,08
0,00
0,00
0,00
0,00
0,00
0,00-100,00%
-0,07
Access this data via the Eulerpool API

Chimerix Analisi delle Azioni

Cosa fa Chimerix? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Chimerix azioni

Su Eulerpool è possibile consultare lo sviluppo storico completo del Chimerix di Rapporto Debiti Totali / EBITDA dal 2006, con valori annuali, grafici e analisi dettagliate.

Debiti/EBITDA misura il debito totale rispetto agli utili prima di interessi, imposte, ammortamenti e accantonamenti. Indica gli anni necessari per ripagare tutto il debito dall'EBITDA.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Chimerix di Rapporto Debiti Totali / EBITDA con i competitor del settore e la media industriale per valutare se è attraente.

Access this data via the Eulerpool API

Leva finanziaria — Chimerix

Tutte le Metriche Finanziarie — Chimerix